3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
18
NIH
5
NETWORK
4
UNKNOWN
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
26
Leukemia
3
Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms by Histologic Type
1
Neoplasm, Residual
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
17
blinatumomab
16
fludarabine
13
Vincristine
11
Cytarabine
10
tisagenlecleucel
8
pegaspargase
8
nilotinib
8
Methotrexate
8
Inotuzumab Ozogamicin
8
Clofarabine
8
venetoclax
7
Dexamethasone
7
asparaginase erwinia chrysanthemi recombinant
6
Dasatinib
6
Azacitidine
5
AP 1903 reagent
5
aflibercept
4
Mercaptopurine
4
Imatinib Mesylate
4
Filgrastim
4
Etoposide
4
Drug Therapy
4
Daunorubicin
4
ponatinib
3
Sensitivity and Specificity
3
Mitoxantrone
3
Immunotherapy, Adoptive
3
Granulocyte Colony-Stimulating Factor
3
CPX-351
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
Idarubicin
×
Clear all
NCT03860844
2025-09-09
ISAKIDS
Sanofi
Phase 2
Terminated
67 enrolled
25 charts